

# Ohio Board of Nursing www.nursing.ohio.gov

17 South High Street, Suite 400 • Columbus, Ohio 43215-7410 • (614) 466-3947

	Original New Drug Ap			
Generic Name	Trade Name	Indication(s)	CPG Action/ May 19, 2014	
January 2014				
Ferric Carboxymaltose	Injectafer	Nutrients & Nutritional Agents: Trace Elements. Indicated for the treatment of iron deficiency anemia in adults with intolerance to	CTP holder may prescribe.	
Formulary Pg. 5		oral iron		
Factor IX Formulary Pg. 7	Rixubis	Hematological Agents: Antihemophilic Agents. Indicated for the prevention and control of bleeding in patients with factor IX deficiency.	In accordance with the SCA.	
Tazarotene Formulary Pg. 24	Fabior	Dermatologic Agents: Retinoids. Indicated for the topical treatment of patients with acne vulgaris in patients 12 years and older.	CTP holder may prescribe.	
Riociguat Oral Formulary Pg. 11	Adempas	Cardiovascular Agents: Vasodilators: soluble Guanylate Cyclase Stimulator. Indicated for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension, to improve exercise capacity and for treatment of adults with pulmonary arterial hypertension.	In accordance with the SCA.	
Vortioxetine Hydrobromide Formulary Pg. 17	Brintellix	Central Nervous System Agents: Antidepressants. Indicated for the treatment of major depressive disorder.	In accordance with the SCA.	
Leuprolide Acetate and Norethindrone	Lupaneta Pack	Antineoplastic Agents: Hormones:	In accordance with the SCA.	

# New Drugs May 2014 (Original New Drug Applications: FDA)

Acatata	Consedetuenin Llevuesses
Acetate	Gonadotropin-Hormone
	Analog/ Progestin
	Combination.
	Indicated for the
	management of initial
	and recurrent painful
	symptoms of
Formulary Pg. 28	endometriosis.
	February 2014
Conjugated Duavee	Endocrine & Metabolic CTP holder may
Estrogens/	Agents: Sex Hormones: prescribe.
Bazedoxifene	EstrogenSelective
	Estrogen Receptor
	Modulator
	Combinations.
	Indicated for the
	prevention of
	postmenopausal
	osteoporosis in women
	with a uterus and
Formulary Pg. 8	treatment of moderate to
	severe vasomotor
	symptoms associated
	with menopause in
	women with a uterus.
Macitentan Opsumit	Cardiovascular Agents: In accordance with
	Vasodilators: Endothelin the SCA.
	Receptor Antagonists.
	Receptor Antagonists. Indicated for the
	Indicated for the
	Indicated for the treatment of pulmonary
Formulary Pg. 11	Indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression.
Formulary Pg. 11 Obinutuzumab Gazyva	Indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression. <i>Antineoplastic Agents:</i> CTP holder may
	Indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression.
	Indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression. Antineoplastic Agents: CTP holder may
	Indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression. Antineoplastic Agents: Monoclonal Antibodies. Indicated for the treatment of patients
	Indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression. Antineoplastic Agents: Monoclonal Antibodies. Indicated for the
	Indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression. Antineoplastic Agents: Monoclonal Antibodies. Indicated for the treatment of patients with previously untreated chronic lymphocytic
Obinutuzumab Gazyva	Indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression. Antineoplastic Agents: Monoclonal Antibodies. Indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia in combination
Obinutuzumab Gazyva Formulary Pg. 28	Indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression.CTP holder mayAntineoplastic Agents: Monoclonal Antibodies. Indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia in combination with chlorambucil.CTP holder may
Obinutuzumab Gazyva	Indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression. Antineoplastic Agents: Monoclonal Antibodies. Indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia in combination
Obinutuzumab Gazyva Formulary Pg. 28	Indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression.CTP holder mayAntineoplastic Agents: Monoclonal Antibodies. Indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia in combination with chlorambucil.CTP holder may
Obinutuzumab Gazyva Formulary Pg. 28	Indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression.CTP holder may NOT prescribe.Antineoplastic Agents: Monoclonal Antibodies. Indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia in combination with chlorambucil.CTP holder may NOT prescribe.Antineoplastic Agents: Kinase Inhibitors. Indicated for theCTP holder may NOT prescribe.Antineoplastic Agents: Kinase Inhibitors. Indicated for theCTP holder may NOT prescribe.
Obinutuzumab Gazyva Formulary Pg. 28	Indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression.CTP holder may NOT prescribe.Antineoplastic Agents: Monoclonal Antibodies. Indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia in combination with chlorambucil.CTP holder may NOT prescribe.Antineoplastic Agents: Monoclonal Antibodies. Indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia in combination With chlorambucil.CTP holder may NOT prescribe.
Obinutuzumab Gazyva Formulary Pg. 28	Indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression.CTP holder may NOT prescribe.Antineoplastic Agents: Monoclonal Antibodies. Indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia in combination with chlorambucil.CTP holder may NOT prescribe.Antineoplastic Agents: Kinase Inhibitors. Indicated for the treatment of mantle cell lymphoma in patientsCTP holder may NOT prescribe.
Obinutuzumab Gazyva Formulary Pg. 28	Indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease 
Obinutuzumab Gazyva Formulary Pg. 28	Indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease 
Obinutuzumab Gazyva Formulary Pg. 28	Indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease 

	Marc	ch 2014	
Filgrastim Formulary Pg. 6	Granix	Hematological Agents: Hematopoietic Agents: Colony-Stimulating Factors. Indicated to reduce the duration of severe neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy associated with a clinically significant incidence of neutropenic fever.	CTP holder may prescribe.
Simeprevir	Olysio	Anti-Infectives, Systemic: Antiviral Agents. Indicated for the treatment of genotype 1 chronic hepatitis C virus in patients with compensated liver	In accordance with the SCA.
Formulary Pg. 23		disease.	
<b>,</b>		<u>il 2014</u>	
Sucroferric Oxyhydroxide Formulary Pg. 5	Velphoro	Nutrients & Nutritional Agents: Trace Elements. Indicated for the control of serum phosphorus levels in patients with chronic kidney disease receiving dialysis.	CTP holder may prescribe.
Coagulation Factor XIII A-Subunit, Recombinant Formulary Pg. 7	Tretten	Hematological Agents: Antihemophilic Agents. Indicated for routine prophylaxis of bleeding in patients with congenital factor XIII A- subunit deficiency.	In accordance with the SCA.
Hydrocodone Bitartrate	Zohydro ER	Central Nervous System Agents: Schedule II Analgesics. Indicated for management of pain severe enough to require around the clock opioid, long-term treatment and for which	In accordance with the SCA.

Formulary Pg. 15		alternative treatment options are inadequate.	
Eslicarbazepine Acetate	Aptiom	Central Nervous System Agents: Anticonvulsants. Indicated for the treatment of partial- onset seizures.	CTP holder may prescribe.
Formulary Pg. 19			
Sofosbuvir	Sovaldi	Anti-infective, Systemic: Antiviral Agents. Indicated for the treatment of chronic	In accordance with the SCA.
Formulary Pg. 23		hepatitis C virus.	

### New Drugs Indications/ Warnings May 2014 (New Drug Indications/ Black Box Warnings' EDA

Generic Name	Drug Indications/ Black Trade Name	Indication(s)	CPG Action/Date
Generic Name		ry 2014	CFG Action/Date
		1	
Human Immune	Gammaplex	Biologic/ Immunologic	Current:
Globulin Intravenous		Agents: Immune	In accordance with
		Globulins.	the SCA
		New indication for the	
		treatment of chronic	May 19, 2014
		immune	No Changes
		thrombocytopenic	
Formulary Pg. 24		purpura.	
	Februa	ary 2014	
Onabotulinumtoxina	Botox Cosmetic	Central Nervous System	Current:
		Agents: Botulinum	In accordance with
		Toxins.	the SCA
		New indication for the	
		temporary improvement	May 19, 2014
		in the appearance of	No Changes
		moderate to severe	
		lateral canthal lines	
		associated with	
		orbicularis oculi activity	
Formulary Pg. 20		in adult patients.	
Rabeprazole Sodium	AcipHex	Gastrointestinal Agents:	Current:
-	-	Proton Pump Inhibitors.	CTP holder may
		New indication for the	prescribe
		treatment of	
		symptomatic GERD in	May 19, 2014
		adults and pediatric	No Changes
		patients 1 year and	
		older.	
Formulary Pg. 20			

Certolizumab Pegol	Cimzia	Biologic/ Immunologic Agents: Immunomodulators. New indications for the for the treatment of adults with active ankylosing spondylitis	Current: In accordance with the SCA May 19, 2014 No Changes
		and active psoriatic	
Formulary Pg. 24		arthritis.	
	Ма	urch 2014	
Tigecycline	Tygacil	Anti-Infectives, Systemic: Glycyclines. New black box warning for an increase in all-	Current: In accordance with the SCA
Formulary Pg. 21		cause mortality.	May 19, 2014 No Changes
Sorafenib	Nexavar	Antineoplastic Agents: Kinase Inhibitors. New indication for the treatment of patients with differentiated	Current: CTP holder may NOT prescribe. May 19, 2014
Formulary Pg. 28		thyroid carcinoma.	No Changes
· • ·	A	pril 2014	· •
None			

# Formulary Revision Request May 2014 (Original New Drug Applications: FDA)

Generic Name	Trade Name	Indication(s)	CPG Action/Date		
Formul	Formulary Review Revision Request from Viaa D. Anderson, APRN				
Aminocaproic Acid	Amicar	Hematological Agents: Hemostatics.	May 19, 2014		
		Indicated for treatment of excessive bleeding.	In accordance with the SCA.		
		Current: CTP holder may NOT prescribe.			
		Requesting: In accordance with the			
Formulary Pg.8		SCA.			

#### Review of Prescribing Designations CTP Holder May NOT Prescribe and in Accordance with the SCA

Central Nervous System Agents (May 2014)

Drug Category/Drug Name	Indications(s)	Current Prescribing Designation	CPG Action/Date
Indille	CNS Stir		
Analeptics	Central Nervous System Agents: CNS	CTP holder May NOT prescribe.	May 19, 2014 No Changes
Doxapram HCL (Doxapram, Dopram)	Stimulants: Analeptics. Indicated for use to stimulate respiration in patients with drug- induced post-anesthesia respiratory depression or apnea, to stimulate respiration, hasten arousal, and encourage return of laryngo- pharyngeal reflexes in patients with mild to moderate respiratory and CNS depression, and as a temporary measure in hospitalized patients with acute		
Formulary Pg. 15	respiratory insufficiency		
Anorexiants	Central Nervous System Agents: Anorexiants. Indicated as a short- term adjunct in a regimen of weight reduction based on caloric restriction.	CTP holder May NOT prescribe.	May 19, 2014 No Changes
Formulary Pg. 15			
	Miscellaneou	s Analgesics	
Ziconotide (Prialt)	Central Nervous Agents: Miscellaneous Agents. Indicated for the management of severe chronic pain in patients for whom intrathecal	CTP holder May NOT prescribe.	May 19, 2014 No Changes
Formulary Pg. 16	therapy is warranted.		
	Antiemetic/Anti	vertigo Agents	
Aprepitant (Emend)	Miscellaneous. Indicated for prevention	CTP holder may prescribe for prescribers	May 19, 2014

Formulary Pg. 16	of nausea/vomiting associated with moderate or highly emetogenic cancer chemotherapy and prevention of postoperative nausea/vomiting.	who have a standard care arrangement with a collaborating Hematologist/ Oncologist. CTP may NOT prescribe for CTP holders who do not have a standard care arrangement with a collaborating Hematologist/ Oncologist.	In accordance with the SCA.
	Antianxiet		
Meprobamate (Equanil, Miltown) Formulary Pg. 16	Antianxiety Agents. Indicated for management of anxiety disorders or short-term relief of the symptoms of anxiety.	CTP holder May NOT prescribe.	May 19, 2014 No Changes
	Antidepr	essants	
Nefazodone (Nefazodone HCL)	Antidepressants. Indicated for the treatment of depression.	In accordance with the SCA.	May 19, 2014 No Changes
Formulary Pg. 17			
MAO Inhibitors	Antidepressants: Monoamine Oxidase Inhibitors. Indicated for use in patients with atypical depression and in some patients unresponsive to other antidepressive therapy.	In accordance with the SCA.	May 19, 2014 No Changes
	Antipsycho	otic Agents	
Clozapine (Clozapine, FazaClo) Formulary Pg. 17	Antipsychotic Agents. Indicated for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder.	In accordance with the SCA.	May 19, 2014 No Changes
Lithium (Lithium Carbonate, Eskalith) Formulary Pg. 17	Antipsychotic Agents. Indicated for the treatment of manic episodes of manic- depressive illness.	In accordance with the SCA.	May 19, 2014 No Changes

Sodium Oxybate (Xyrem) Formulary Pg. 17	Miscellaneous Psychotherapeutic Agents. Indicated for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy.	In accordance with the SCA.	May 19, 2014 No Changes
	Sedatives and Hypno	tics, Nonbarbiturate	
Paraldehyde (Paral)	Sedatives and Hypnotics, nonbarbiturate. Indicated to quiet patients and produce sleep in delirium tremens and in other psychiatric states characterized by excitement.	CTP holder May NOT prescribe.	May 19, 2014 No Changes
Formulary Pg. 18	aral Anosthotics: Barhitu	rates, Gases, Volatile Liqu	uds
	General Anesthetics.	· · · ·	
Barbiturates, Gases, Volatile Liquids Formulary Pg. 18	Indicated for the induction of anesthesia, and for short surgical procedures.	CTP holder May NOT prescribe. Except CTP holders may prescribe Ketamine, Propofol, or Etomidate in an institutional setting per institutional standards for urgent and emergent respiratory care.	May 19, 2014 No Changes
	Anticon	vulsants	
Vigabatrin (Sabril)	Anticonvulsants. Indicated for infants and children with infantile spasms for whom the potential benefits outweigh the potential risk of vision loss and as an adjunctive therapy for adults with refractory complex partial seizures.	CTP holder May NOT prescribe.	May 19, 2014 No Changes
Formulary Pg. 19	Marala D. L. C. A.		
	Muscle Relaxants – Ac		
Muscle Relaxants – Adjuncts to Anesthesia	Muscle Relaxants – Adjuncts to Anesthesia. Indicated as an adjunct to general anesthesia to	CTP holder May NOT prescribe. Except that a CTP holder may prescribe rocuronium	May 19, 2014 In accordance with the SCA only in institutional settings

Formulary Pg. 19	facilitate endotracheal intubation; to relax skeletal muscle during surgery or mechanical ventilation.	bromide or succinylcholine chloride in an institutional setting per institutional standards for urgent and emergent respiratory care.	per institutional standards for urgent and emergent respiratory care.
	Adenosine	Phosphate	
Adenosine Phosphate	Adenosine Phosphate. Indicated for symptomatic relief of complications with stasis dermatitis	In accordance with the SCA.	May 19, 2014 No Changes
Formulary Pg. 20	(varicose veins).		
Riluzole (Rilutek)	<i>Riluzole.</i> Indicated for the treatment of patients with amyotrophic lateral sclerosis. Riluzole extends survival and/or	In accordance with the SCA.	May 19, 2014 No Changes
Formulary Pg. 20	time to tracheostomy.		
	Physical	Adjuncts	
Calcium Hydroxylapatite Implant (Radiesse)	<i>Physical Adjuncts.</i> For the restoration and/or correction of the signs of facial fat loss in persons with HIV and for subdermal implantation for the correction of moderate to severe facial wrinkles	CTP holder May NOT prescribe.	May 19, 2014 No Changes
Formulary Pg. 20 Poly-L-Lactic Acid (Sculptra) Formulary Pg. 20	and folds. <i>Physical Adjuncts.</i> For restoration and/or correction of the signs of facial fat loss in people with HIV.	CTP holder May NOT prescribe.	May 19, 2014 No Changes
	Botulinur	m Toxins	
Botulinum Toxins Type A (Botox, Dysport, Xeomin)	Botulinum Toxins: Botulinum Toxins Type A. Indicated for the treatment of severe primary axillary hyperhydrosis, treatment of cervical dystonia, prophylaxis of	In accordance with the SCA.	May 19, 2014 No Changes

Formulary Pg. 20 Rimabotulinumtoxin B (Myobloc)	headaches in adults with chronic migraine, for the temporary improvement in the appearance of moderate to severe glabellar lines associated with currugator and/or procerus muscle activity in adults 65 years of age and younger, treatment of strabismus and blepharospasm associated with dystonia, and treatment of upper limb spasticity in adults. Botulinum Toxins: Botulinum Toxin Type B. Indicated for the treatment of adults with cervical dystonia.	In accordance with the SCA.	May 19, 2014 No Changes
Formulary Pg. 20			
	Tetrabe	nazine	
Tetrabenazine (Xenazine) Formulary Pg. 20	<i>Tetrabenazine.</i> Indicated for the treatment of chorea associated with Huntington disease.	CTP holder may NOT prescribe.	May 19, 2014 No Changes